Octave Strengthens Clinical Expertise in MS and Neurodegenerative Disease – Read the Release
Octave Strengthens Clinical Expertise in MS and Neurodegenerative Disease – Read the Release
What MSDA results prompt which changes in clinical decisions?
Demonstrates utility through objective treatment plan changes.
Three patterns in clinician MS management were observed following receipt of MSDA results : 1) A low MSDA score supported the clinician’s plan to continue the current treatment plan, 2) A low MSDA score helped determine when a patient could discontinue a DMT, and 3) A high MSDA score identified when a patient should initiate a DMT
(FIG. 5).
Treatment change trends were most common among low & high MSDA scores, instilling confidence in staying the course and DMT stop, start and switch.
